Lurasidone 40 mg

DRUG3 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

PharmacokineticsSchizophrenia

Phase 1

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

CompletedNCT00549666

Sumitomo Pharma America, Inc.Pharmacokinetics

Start: 2007-08-31End: 2007-12-31Updated: 2011-09-14

Phase 2

Safety and Tolerability Study of Drug to Treat Schizophrenia

CompletedNCT00044005

Sumitomo Pharma America, Inc.Schizophrenia

Start: 2002-09-30End: 2003-11-30Updated: 2014-04-17

Phase 3

Pediatric Schizophrenia Efficacy and Safety Study

CompletedNCT01911429

Sumitomo Pharma America, Inc.Schizophrenia

Start: 2013-08-31End: 2015-12-31Updated: 2017-04-18

Related Papers

Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy

Schizophrenia Bulletin Open2022-01-018 citations

The Efficacy and Safety of Lurasidone in Adolescent Patients with Schizophrenia: Results of Functional and Quality of Life Measures from a 6-week, Double-blind, Placebo-controlled Study

European Psychiatry2017-04-011 citations

The Efficacy of Lurasidone on PANSS Subscales in Adolescent Patients with Schizophrenia: Results from a 6-week, Double-blind, Placebo-controlled, Multicenter Study

European Psychiatry2017-04-011 citations

149. Effect of Lurasidone on Quality of Life, Function, and Metabolic Parameters in Adolescent Patients With Schizophrenia: Results From a 6-Week, Double-Blind, Placebo-Controlled Study

Schizophrenia Bulletin2017-03-011 citations

SA114. Lurasidone for the Treatment of Adolescent Patients With Schizophrenia: Effect on PANSS Subscales

Schizophrenia Bulletin2017-03-011 citations